cDNA) expression than, for example, Scheuring et al, who used 20 000 copies/ml as the cutoff.
Imatinib mesylate (IM) has now become the first-line standard therapy for patients with newly diagnosed CML. 1 Recent data showed, however, that resistance to IM can develop in patients in more aggressive phases of their disease, due to a variety of mechanisms including ABL kinase domain mutations that interfere with IM binding. [2] [3] [4] Although the mechanisms of the occurrence of such mutations remain poorly understood, it has been shown that they can occur prior to the introduction of IM, suggesting the possibility of a clonal selection under IM therapy in some patients. 5 It is however possible that mutations could also occur during IM therapy.
To determine if ABL kinase domain mutations could occur de novo in primary marrow cells expressing a BCR-ABL transgene, BCR-ABL ecotropic retrovirus (MIGR-p210 BCR-ABL ) was used to infect 5-FU-treated bone marrow cells harvested from C57BL/6 mice, as described previously. 6 When transplanted in lethally irradiated animals, the retrovirally transduced cells (30% GFP þ ) induced leukemia within 3 weeks. The generation of BCR-ABL-induced leukemia after BCR-ABL transduction of 5-FU-treated murine bone marrow cells has also been demonstrated by other teams. 7, 8 Both BCR-ABL-transduced and control C57BL/6 bone marrow cells were seeded in liquid cultures at 10 4 cells/ml in DMEM medium supplemented with 10% fetal calf serum, in the presence of 0.25 mM IM. The medium was weekly half changed concomitantly with gradual increase of IM concentration from 0.25 to 2 mM over a 2-month period of culture. In these conditions, significant growth on IM was observed in 10/192 wells containing BCR-ABLtransduced cells, compared to 0/192 wells containing normal bone marrow cells. IM-resistant cells were then cultured in the presence of the murine stromal MS-5 cell line and 2 mM IM for over 6 months, eventually leading to the persistent growth of two clones (C3 and C10) that were amplified for further characterization. At cytological analysis, both cell lines had a typical mast cell morphology. Flow cytometry analyses demonstrated the presence of CD41 marker on both cell lines, with the absence of myeloid (Gr1), erythroid (Ter119) and B-cell (B220) markers. Cells were not polyploid, and interestingly, they exhibited higher growth rates in the presence of IM, with reduced growth upon IM deprivation. Both cell lines had evidence of BCR-ABL vector integration by PCR analysis and were highly GFP þ .
These cells being selected in the presence of IM, we determined the IC 50 for this drug in both cell lines. The IC 50 values were found to be very high (20 mM) for both cell lines (data not shown).
To further characterize these cells, we extracted high molecular weight genomic DNA and amplified a BCR-ABL fragment of 1236 bp encompassing the BCR-ABL junction and the ABL kinase domain of the integrated construct. We then sequenced a 622 bp fragment using internal primers, in both 5 0 and 3 0 directions. Plasmid DNA from the original MIGRp210 BCR-ABL vector was sequenced as control. Surprisingly, three ABL kinase domain point mutations were readily detectable in both clones as compared to the original BCR-ABL retroviral vector, which retained a nonmutated BCR-ABL sequence ( Figure 1a ). These mutations corresponded to A-to-G transitions, all leading to amino-acid changes. Clone C3 carried two mutations interesting the catalytic helix (E281K) and the SH2 contact region (E352K) of ABL kinase domain, whereas clone C10 carried a single mutation in the catalytic helix (D276N) (Figure 1b) . Thus, the development of IM resistance of bone marrow-derived cells was associated with the occurrence of de novo ABL kinase domain mutations.
Mutations affecting the residue D276 were previously reported in studies using either an in vitro mutagenesis strategy (D276V) 9 or IM selection of BCR-ABL þ Ba/F3 cells (D276G), 10 leading in both cases to IM resistance. Likewise, E281K and E352K mutations were both previously described and shown to induce IM resistance in BCR-ABL þ cells. 9, 10 Given their significant degree of IM resistance, mutations affecting the catalytic a1 helix (D276 and E281 residues) are likely to be clinically problematic. Indeed, D276G mutation was recently described in one patient affected by Ph þ acute lymphoblastic leukemia, as well as one CML patient in chronic phase, who both developed IM resistance. 11 To our knowledge, our study is the first demonstrating the occurrence of the D276N substitution in the context of IM resistance. The side chain of residue E352 is predicted to face the SH2 domain of BCR-ABL and may therefore be involved in the specificity of contacts along this surface. E352K substitution thus might play a role in preventing the appearance of the autoinhibited conformation of ABL. 1 BMS354825 is able to inhibit in vitro and in vivo 14 of 15 imatinib-resistant Bcr-Abl mutants, while the T315I was clearly resistant to the compound. 1 It has been suggested that BMS354825 could fit into a conformation of Abl different from the inactive one (ie the one that imatinib preferentially binds). 1 To better understand imatinib and BMS354825 binding, the two molecules were docked using the FLEXX software 2 in different available structures of Abl: 1IEP Abl (closed conformation) in which the activation loop is closed, and 1M52 Abl (intermediate conformation) where the activation loop is open. 3 In both structures, the highly conserved DFG motif has a similar conformation, with the phenylalanine residue pointing towards the ATP binding site, while the aspartic acid residue points away from it (Figure 1a) , indicating that the enzyme is still in its inactive form, that is, the one unable to perform the catalytic reaction. Furthermore, a model of Abl with the DFG in the productive conformation, with the aspartic acid residue pointing towards the ATP binding pocket and the activation loop in the open conformation (similar to those seen in the 1IR3 conformation 4 and in the human lympocyte kinase structure 3LCK 5 ), was generated (open conformation) to study the effect of its orientation on the binding mode of these compounds. The used docking protocol allowed us to reproduce accurately the available binding orientations of imatinib and PD173955, as previously determined on crystal structures.
As shown in Figure 1a and b, BMS354825 binds, at difference with imatinib, both conformations of Abl, although in an opposite orientation. In fact, while the piperazine moiety of BMS354825 is aligned to the one of imatinib in the closed conformation (Figure 1a) , it points in the opposite direction in the intermediate conformation. In the latter case, BMS354825 assumes a binding orientation very similar to the nanomolar inhibitor PD173955. 3 In both cases, BMS354825 establishes the same number of H bonds with Abl residues (Figure 1b (Figure 1a) , it adopts a bended one in the active conformation Abl model. This bending of the molecule is similar to the one seen for imatinib in the human spleen tyrosine kinase (1XBB). 6 Noteworthy is the fact that the IC 50 value of imatinib for the human spleen tyrosine kinase is in the micromolar range. 6 The binding mode predicted for BMS354825 in the open conformation of Abl does not allow tight binding to the protein and a micromolar IC 50 value could be expected for this conformation, in contrast to the experimentally determined nanomolar IC 50 values. 1 This suggests that the putative binding mode of BMS35425 in the active conformation should not be the pharmacologically relevant one. On the contrary, the snug fit and hydrogen bond pattern of observed with the closed and intermediate conformations of the protein (Figure 1a) can explain the nanomolar IC 50 values of BMS354825.
Taken together, our docking results suggest that the active conformation of Abl is not favorable for the binding of BMS354825. This is mainly due to the fact that the conformation of the aspartic acid residue of the DFG motif substantially changes the electrostatic characteristics of the ATP binding pocket. Furthermore, Figure 1 shows that BMS354825 closely interacts with T315, which can either form a hydrogen bond to the nitrogen or the oxygen of the amide group of the BMS354825 compound (in Figure 1b , the hydrogen bond to the oxygen is shown). It is in fact known that residue 315 of Abl is not required for ATP binding as indicated by previously published data on ATP affinity. 7 The refractoriness of the T315I mutant of BCR/ABL to BMS354825 further indicates that this compound indeed binds to the inactive form of Abl, as imatinib does, although requiring a lower conformational stringency, with the ability of binding more intermediate conformations than imatinib. These findings provide further evidence that BMS354825 cannot strictly be defined as true ATP-competitive inhibitor as indicated by Shah et al. 1 Considering the fact that BMS354825 inhibits several Abl mutants and that the intermediate conformation of Abl is less restrictive
